| |
News

February 27th , 2012 – The Spanish biotechnological companies, Biotools and 2B BlackBio, reach an agreement with the Mexican pharmaceutics Silanes Laboratories.
- Biotools and 2B BlackBio, have reached an agreement on technology transfer and licensing of manufacturing of their products in the fields of molecular diagnosis and personalized medicine.
- After this agreement, Silanes Laboratories will be able to make and to commercialize the diagnosis systems patented by the Spanish companies, as well as to develop new products and systems based on the technologies transferred.
The Spanish companies Biotools and 2B BlackBio have signed a global license agreement of products and transference of technology, in the fields of molecular diagnosis and personalized medicine with the Mexican pharmaceutics Silanes Laboratories.
This agreement will allow Silanes Laboratories to make and to commercialize diagnostic kits based on nucleic acid amplification technologies and stabilization of complex reaction mixtures ("Gelification") patented by Biotools, and on the "accelerated high-sensitivity microsequencing patent" by 2B BlackBio, as well as to develop new products and systems based on the transferred technologies.
Silanes Laboratories has 68 years of experience in the pharmaceutical market and medical prescription. In addition it invests 10% of its sales in research and development at national level, in countries like Spain and the United States, and also has a portfolio of 100 health products. Silanes Laboratories is, in Mexico, the leading manufacturer of combined oral antidiabetics, manufacturing annually 1600 million tablets, taking care of million patients who live with diabetes mellitus type 2 in Mexico, South America, Central America and the Caribbean. In the field of Biotechnology is an international leader in research, development, manufacture and marketing of Fabotherapics, protected by international patents, and it is the only company in Latin America obtaining an FDA approval for an innovating biotechnological product.
Founded in 2009, 2B BlackBio is positioned as a leader in the fields of personalized medicine, medical diagnostics and pharmacogenomics by providing solutions through high-sensitive microsequencing, focusing its developments in the areas of metabolism, oncology, cardiovascular and microbiology. Also,2B BlackBiohas an applied genetics division named Genotest offering a wide range of genetic analyses services in the fields of nutrition, sport, metabolic diseases, affections cardiovascular diseases and personalized treatment of cancer.
Biotools B & M Labs, SA, located in Spain and with branch offices in Brazil, is one of the main companies of biotechnology in the field of reagents, applications and technologies in the area of molecular biology in Europe. It has a global sales network in Latin America and Asia, with a wide range of products and international patents.
|